Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...

A large-scale clinical trial found that intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) analog medication, during heart surgeries involving bypass did not significantly reduce ...

Type 2 diabetes is a long-term condition where the body struggles to manage sugar levels in the blood. Normally, doctors ...

New research suggests a surprising benefit of this medication, and how it can lower the risk of getting cancer.

New research being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May) and published in ...

Share on Pinterest A new study shows GLP-1 drugs liraglutide, exenatide, and dulaglutide were 41% more effective at preventing obesity-related cancers. Carsten Snejbjerg/Bloomberg via Getty Images ...

Exenatide ext-rel 2mg; susp for SC inj; contains sucrose. Exenatide activates the GLP-1 receptor, thereby increasing intracellular cyclic AMP (cAMP) in beta cells leading to glucose-dependent ...

The research explored a combination of two additional diabetes medications: dapagliflozin and exenatide. Scientists wanted to ...

All subjects in the NPM-115 cohort had successful insertions of a miniature, ultra long-acting GLP-1 (exenatide) implant in ...

Longer-acting glucagon-like peptide-1 (GLP-1) receptor agonists and devices have been recently developed and include once-weekly exenatide, dulaglutide, albiglutide, semaglutide and miniosmotic ...

New research suggests that weight loss injections, also known as GLP-1 receptor agonists, may have a significant anti-cancer ...